NCT01582009 - Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions

Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer

Interventions

DRUG

panobinostat

Given orally

DRUG

everolimus

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

OTHER

liquid chromatography

Correlative studies

OTHER

mass spectrometry

Correlative studies

OTHER

enzyme-linked immunosorbent assay

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

Trial Locations (2)

Roswell Park Cancer Institute, Buffalo

University of Rochester Medical Center, Rochester